US President Obama signs health reform bill, but Republicans will fight on

24 March 2010

At a White House ceremony yesterday morning, just two days after the measure was passed by the House of Representatives, US President Barack Obama signed the health care reform bill into law. However, according to observers, and as mentioned in The Pharma Letter's previous reporting, the debate has just begun.

Philip Klein, Washington Correspondent for The American Spectator, comments: 'For liberals, the legislation doesn't go far enough. And in the coming years, they will continue to push for tighter regulations on insurance companies, higher subsidies for purchasing coverage and for the inclusion of a government-run plan in the exchanges. Further, those who still believe the legislation is insufficient will continue to press for a single-payer system.'

In the meantime, he says, 'conservatives will begin the immediate drive to legally overturn and/or legislatively repeal the health care bill, or at least scale back its major provisions. Even if none of the efforts to overturn or repeal the health care legislation finds success, the implementation of 'Obamacare' will help clarify for the American people what it means to have the government take such an active role in the medical system.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical